ABOUT

ABOUT

Precision Cancer Medicine is now. We provide molecular genetic tests and services for healthcare, biopharmaceutical companies, and academia. Based on leading research from Lund University, Sweden, our proprietary and patent-pending molecular genetic tests are part of a revolution in cancer companion diagnostics and monitoring.

Our tests quantify circulating tumor DNA (ctDNA) — a powerful new biomarker — to detect cancer, measure response to therapy, and decipher the cancer-specific DNA mutations that may be targetable with clinically-approved drugs or therapies currently in clinical trials.

Unique and unprecedented accuracy and sensitivity, with a lower limit of detection that is 10 to 100-fold improved compared to other NGS methods. Our analyses detect what others miss.

The right drug — for the right patient — at the right time.

SERVICES

Contact us for your Personalized Solution.
Gene Mutation Analysis

Gene Mutation Analysis

  • Companion diagnostics for clinically-relevant gene mutations such as BRAF, EGFR, and KRAS.
  • Custom analyses for your genes and mutations of interest.
  • Patent-pending IBSAFE™ technology, sensitive to 0.001%.
  • ctDNA or tissue biopsy testing.

Circulating Tumor DNA

Circulating Tumor DNA

  • Companion diagnostics for clinically-relevant gene mutations such as BRAF, EGFR, and KRAS.
  • Custom analyses for your genes and mutations of interest.
  • Patent-pending IBSAFE™ technology, sensitive to 0.001%.
  • Quantitative: copies/volume.

Chromosome Analysis

Chromosome Analysis

  • Chromosomal rearrangements are tumor-specific trunk markers maintained in most subclones.
  • Personalized analyses for minimal residual disease, occult metastasis, and therapy response.
  • Proprietary KROMA™ technology.
  • Non-invasive blood test.

SCIENCE

Cell-free DNA is released by normal cells and cancerous cells into the blood stream and other body fluids. Advanced molecular technologies such as those developed by SAGA Diagnostics are required to distinguish the tumor-derived DNA (“circulating tumor DNA” or ctDNA) from the normal-cell-derived DNA. Recent research indicates ctDNA to be a robust biomarker for tumor burden and that it faithfully represents the genetic defects present in tumor deposits. Therefore, ctDNA holds great promise for non-invasive monitoring of cancer patients.

The quantity of ctDNA is related to prognosis, and ctDNA analyses can be used to detect druggable gene mutations as well as resistance mutations at the earliest moment.

Compared to the traditional blood biomarkers and even circulating tumor cells, evidence to date suggests ctDNA to be more sensitive and specific and informative of therapy response earlier than what can be seen by imaging modalities such as CT/MRI scans.



LATEST NEWS

TEAM

We are driven to provide innovative companion diagnostics and circulating tumor DNA analyses to transform cancer care.
Click here to view the full team.